Envista Holdings Co. (NYSE:NVST) – Analysts at Piper Sandler lifted their FY2021 earnings per share estimates for Envista in a research report issued to clients and investors on Tuesday, August 3rd. Piper Sandler analyst J. Bednar now expects that the company will earn $1.94 per share for the year, up from their prior estimate of $1.90. Piper Sandler currently has a “Neutral” rating and a $47.00 target price on the stock. Piper Sandler also issued estimates for Envista’s Q4 2021 earnings at $0.47 EPS, Q1 2022 earnings at $0.51 EPS, Q2 2022 earnings at $0.56 EPS, FY2022 earnings at $2.05 EPS and FY2023 earnings at $2.20 EPS. Envista (NYSE:NVST) last released its earnings results on Tuesday, August 3rd. The company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.09. Envista had a net margin of 5.00% and a return on equity of 6.93%.
Other analysts also recently issued research reports about the stock. TheStreet raised shares of Envista from a “d+” rating to a “c” rating in a research report on Thursday, May 13th. Zacks Investment Research raised shares of Envista from a “hold” rating to a “strong-buy” rating and set a $52.00 price objective for the company in a research report on Saturday, May 8th. Credit Suisse Group raised their price objective on shares of Envista from $49.00 to $55.00 and gave the stock an “outperform” rating in a research report on Thursday, May 6th. Finally, Morgan Stanley raised their price objective on shares of Envista from $42.00 to $46.00 and gave the stock an “equal weight” rating in a research report on Friday, May 7th. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $43.67.
NYSE:NVST opened at $40.54 on Thursday. The firm has a market cap of $6.52 billion, a P/E ratio of 59.62, a PEG ratio of 0.86 and a beta of 1.93. The firm’s 50 day moving average price is $42.89. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.02 and a quick ratio of 0.77. Envista has a fifty-two week low of $22.47 and a fifty-two week high of $46.52.
A number of large investors have recently modified their holdings of the business. GSA Capital Partners LLP lifted its stake in Envista by 9.4% during the 2nd quarter. GSA Capital Partners LLP now owns 5,454 shares of the company’s stock valued at $236,000 after acquiring an additional 470 shares in the last quarter. Artemis Investment Management LLP lifted its stake in Envista by 23.4% during the 2nd quarter. Artemis Investment Management LLP now owns 1,020,210 shares of the company’s stock valued at $44,115,000 after acquiring an additional 193,651 shares in the last quarter. New York State Common Retirement Fund lifted its stake in Envista by 5.3% during the 2nd quarter. New York State Common Retirement Fund now owns 191,246 shares of the company’s stock valued at $8,264,000 after acquiring an additional 9,670 shares in the last quarter. Eagle Bay Advisors LLC bought a new position in Envista during the 2nd quarter valued at $39,000. Finally, North Star Asset Management Inc. bought a new position in Envista during the 2nd quarter valued at $2,999,000.
In related news, General Counsel Mark E. Nance sold 14,263 shares of Envista stock in a transaction on Friday, June 11th. The shares were sold at an average price of $44.05, for a total value of $628,285.15. Following the completion of the sale, the general counsel now owns 34,327 shares of the company’s stock, valued at approximately $1,512,104.35. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Howard H. Yu sold 35,021 shares of Envista stock in a transaction on Friday, May 7th. The shares were sold at an average price of $45.17, for a total transaction of $1,581,898.57. Following the completion of the sale, the chief financial officer now directly owns 66,297 shares of the company’s stock, valued at approximately $2,994,635.49. The disclosure for this sale can be found here. In the last three months, insiders sold 75,166 shares of company stock valued at $3,330,489. 0.82% of the stock is currently owned by insiders.
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company’s Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands.
Recommended Story: Net Margin – Understanding the Different Kinds of Profit
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Envista, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Envista wasn’t on the list.
While Envista currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.